'LONDON (Reuters) - AstraZeneca Plc suffered its third setback in two months on Friday as lung cancer drug Iressa failed to help patients live longer in a major clinical trial, sending its shares down more than 8 percent. '
This is after a trial of 1692 patients . It failed to do better than the placebo in extending life in NSCLC patients . OSIP , manuf of Tarciva , a drug already proven to extend life in NSCLC jumped 45% on the news , to $US68.38 for a market cap of 3.46B .
NSCLC is one of the possible targets of Solbecs Coramsine .
- Forums
- ASX - By Stock
- SBP
- iressa fails
SBP
solbec pharmaceuticals limited
iressa fails
Add SBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
Previous Video
Next Video
SPONSORED BY The Market Online